SIGNIFICANT ACCOUNTING POLICIES (Details) $ / shares in Units, $ in Thousands							1 Months Ended	3 Months Ended		6 Months Ended
	Jul. 02, 2021 USD ($) $ / shares shares	May 13, 2021 USD ($)	Feb. 17, 2021 USD ($) $ / shares shares	Feb. 10, 2021 USD ($)	Jul. 23, 2018 USD ($)	Oct. 19, 2017 USD ($)	Oct. 31, 2015	Jun. 30, 2021 USD ($) agreement $ / shares shares	Jun. 30, 2020 $ / shares shares	Jun. 30, 2021 USD ($) agreement $ / shares shares	Jun. 30, 2020 $ / shares shares	Dec. 31, 2020 USD ($)
Significant Accounting Policies [Line Items]
Number of shares issued (in shares) | shares			8,749,999
Common Stock, Par or Stated Value Per Share | $ / shares								$ 0.001	$ 0.001	$ 0.001	$ 0.001
Gross proceeds			$ 40,200							$ 8,575
Shares Issued, Price Per Share | $ / shares			$ 4.60
Convertible Debt, Current								$ 56,355		$ 56,355		$ 54,427
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares								25,874,641	25,997,289	26,322,164	18,445,764
ATM Shares
Significant Accounting Policies [Line Items]
Number of shares issued (in shares) | shares	3,296,123
Common Stock, Par or Stated Value Per Share | $ / shares	$ 0.001
Sale of stock, maximum offering price	$ 20,000
Gross proceeds	$ 13,800
2021 Notes [Member] | Convertible Notes Payable [Member]
Significant Accounting Policies [Line Items]
Interest rate (as a percent)								7.50%		7.50%
Amended Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member] | Brazil [Member]
Significant Accounting Policies [Line Items]
Collaborative Arrangement Revenues and Expenses Sharing Percentage							100.00%
Chiesi Agreements [Member]
Significant Accounting Policies [Line Items]
Revenue, Performance Obligation, Number | agreement								2		2
Chiesi US Agreement [Member]
Significant Accounting Policies [Line Items]
Additional Amounts Payable To Cover Development Costs					$ 20,000
Maximum Entitlement Of Development Costs To Cover Per Year					7,500
Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones					$ 760,000
Chiesi US Agreement [Member] | Minimum [Member]
Significant Accounting Policies [Line Items]
Payment On Net Sales Percentage					15.00%
Chiesi US Agreement [Member] | Maximum
Significant Accounting Policies [Line Items]
Payment On Net Sales Percentage					40.00%
Chiesi Ex US Agreement [Member]
Significant Accounting Policies [Line Items]
Additional Amounts Payable To Cover Development Costs						$ 25,000
Maximum Entitlement Of Development Costs To Cover Per Year						10,000
Agreement Amendment Payment Receivable		$ 10,000
Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones		$ 25,000
Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones						$ 320,000
Chiesi Ex US Agreement [Member] | Minimum [Member]
Significant Accounting Policies [Line Items]
Payment On Net Sales Percentage						15.00%
Chiesi Ex US Agreement [Member] | Maximum
Significant Accounting Policies [Line Items]
Payment On Net Sales Percentage						35.00%
SarcoMed USA, Inc. Agreement [Member]
Significant Accounting Policies [Line Items]
License Agreement, Initial Cash Payment				$ 3,500
Term to sign supply agreement				60 days
Chiesi US Agreement and Chiesi Ex US Agreement [Member]
Significant Accounting Policies [Line Items]
Upfront Nonrefundable Non-Creditable Payment Receivable					$ 25,000	$ 25,000